CorMedix (CRMD) Research & Development (2010 - 2025)

CorMedix has disclosed Research & Development across 15 years of filings, most recently posting $8.6 million for Q4 2025.

• Research & Development for Q4 2025 came in at $8.6 million, up 398.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.3 million (up 390.44% YoY), and the FY2025 annual result was $19.3 million, up 390.44% from the prior year.
• Research & Development came in at $8.6 million for Q4 2025 at CorMedix, up from $5.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $8.6 million in Q4 2025 to a low of $650988.0 in Q2 2024.
• The 5-year median for Research & Development is $2.7 million (2021), against an average of $3.0 million.
• Across the five-year window, Research & Development slumped 86.42% in 2024 and surged 601.07% in 2025, its largest moves.
• CorMedix's Research & Development stood at $3.2 million in 2021, then decreased by 12.12% to $2.8 million in 2022, then fell by 19.5% to $2.3 million in 2023, then decreased by 24.57% to $1.7 million in 2024, then soared by 398.14% to $8.6 million in 2025.
• The last three Research & Development figures came in at $8.6 million (Q4 2025), $5.1 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.